

## You are invited to the

### 3<sup>rd</sup> Workshop: Biomedical Applications of Engineered Antibodies and Proteins

Venue: Advanced Engineering Building - AEB (Building 49)  
Staff Road, University of Queensland, St Lucia

## Friday 29<sup>th</sup> Sept 2017

#### Confirmed Speakers List

Dr Trent Munro (AMGEN)  
Dr Evan Shave (Patheon Biologics)  
Dr Catherine Owczarek (CSL Ltd)  
Dr Melinda Dean (Australian Red Cross Blood Service)  
A/Prof Joanne Macdonald (University of the Sunshine Coast)  
Dr Douglas Campbell (Minomic International Ltd)  
Dr Simon Puttick (AIBN/CSIRO)  
Prof Peter Hudson (AVIPEP)  
Prof Kirill Alexandrov (Institute for Molecular Biosciences)  
Dr Tianlei Ying (Fudan University, Shanghai)

This **free** workshop will focus on the latest developments in antibody engineering across a variety of applications that include diagnostic/bioanalytical reagents and associated medical devices, imaging/theranostics, biologic medicines and targeted nanomedicines.

This seminar workshop, run jointly by the *ARC Training Centre for Biopharmaceutical Innovation, University of Queensland* and the *ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash University*, will include presentations from invited experts from across the field.

Click the following link for registration (for catering purposes):

<https://www.eventbrite.com.au/e/biomedical-applications-of-engineered-antibodies-and-protein-workshop-tickets-36089141594>

#### Chairs:

Simon Corrie: [simon.corrie@monash.edu](mailto:simon.corrie@monash.edu)  
Stephen Mahler: [s.mahler@uq.edu.au](mailto:s.mahler@uq.edu.au)

TIME	SESSION DETAILS
8:30AM	<b>COFFEE &amp; REGISTRATION</b> <b>(Speakers please load presentations for next session)</b>
9:15AM	Welcome from Prof Stephen Mahler and Dr Simon Corrie (Chairs)
9:30AM	Dr Trent Munro (AMGEN) <i>Challenges of developing multi-specific antibodies.</i>
10:00AM	Dr Catherine Owczarek (CSL Ltd) <i>CSL311, a novel therapeutic mAb for the treatment of inflammatory diseases mediated by the common beta chain of the GM-CSF, IL-3 and IL-5 receptors.</i>
10:30AM	Dr Evan Shave (Patheon Biologics) <i>Tech Transfer and Flexible Manufacturing of Biopharmaceuticals</i>
11:00AM	<b>MORNING TEA</b> <b>(Speakers please load presentations for next session)</b>
11:30AM	Dr Tianlei Ying (Fudan University, Shanghai) <i>Antibody-based therapeutics for the treatment of infectious diseases</i>
12:00PM	Prof Peter Hudson (Avipep) <i>Antibody-directed cancer therapies; from drug-conjugate ADCs to CarTs (T-cell retargeting)</i>
12:30PM	Dr Melinda Dean (Australian Red Cross Blood Service) <i>ENU mutagenesis as a tool for discovery of novel haematological phenotypes and a platform for antibody discovery</i>
1:00PM	<b>LUNCH</b> <b>(Speakers please load presentations for next session)</b>
2:00PM	Dr Douglas Campbell (Minomic International Ltd) <i>Development of anti-GPC-1 antibody therapeutics</i>
2:30PM	Prof Kirill Alexandrov (Institute for Molecular Biosciences) <i>Using in vitro protein expression and AlphaLISA to rapidly validate and rank protein:protein interactions</i>
3:00PM	<b>AFTERNOON TEA</b> <b>(Speakers please load presentations for next session)</b>
3:30PM	A/Prof Joanne Macdonald (University of the Sunshine Coast) <i>Engineered bacterial enzymes for detoxification of cocaine and nerve agents in humans.</i>
4:00PM	Dr Simon Puttick (AIBN/CSIRO) <i>Image guided physiologically based pharmacokinetic (PBPK) modelling of antibody and recombinant fragment theranostics)</i>
4:30PM	<b>SOCIAL/NETWORKING</b>